- Home
- VMEO vs GHRS Comparison
VMEO vs GHRS Comparison
Compare VMEO & GHRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMEO
- GHRS
- Stock Information
- Founded
- VMEO 2004
- GHRS 2018
- Country
- VMEO United States
- GHRS Ireland
- Employees
- VMEO N/A
- GHRS N/A
- Industry
- VMEO Computer Software: Prepackaged Software
- GHRS Biotechnology: Pharmaceutical Preparations
- Sector
- VMEO Technology
- GHRS Health Care
- Exchange
- VMEO Nasdaq
- GHRS Nasdaq
- Market Cap
- VMEO 622.9M
- GHRS 523.4M
- IPO Year
- VMEO N/A
- GHRS 2021
- Fundamental
- Price
- VMEO $5.05
- GHRS $8.23
- Analyst Decision
- VMEO Buy
- GHRS Strong Buy
- Analyst Count
- VMEO 3
- GHRS 3
- Target Price
- VMEO $5.33
- GHRS $36.67
- AVG Volume (30 Days)
- VMEO 1.3M
- GHRS 26.0K
- Earning Date
- VMEO 11-04-2024
- GHRS 09-03-2024
- Dividend Yield
- VMEO N/A
- GHRS N/A
- EPS Growth
- VMEO N/A
- GHRS N/A
- EPS
- VMEO 0.19
- GHRS N/A
- Revenue
- VMEO $421,083,000.00
- GHRS N/A
- Revenue This Year
- VMEO N/A
- GHRS N/A
- Revenue Next Year
- VMEO $3.00
- GHRS N/A
- P/E Ratio
- VMEO $26.10
- GHRS N/A
- Revenue Growth
- VMEO 0.47
- GHRS N/A
- 52 Week Low
- VMEO $3.02
- GHRS $5.05
- 52 Week High
- VMEO $5.77
- GHRS $14.99
- Technical
- Relative Strength Index (RSI)
- VMEO 57.07
- GHRS 27.06
- Support Level
- VMEO $5.15
- GHRS $8.01
- Resistance Level
- VMEO $5.38
- GHRS $12.11
- Average True Range (ATR)
- VMEO 0.17
- GHRS 1.03
- MACD
- VMEO -0.04
- GHRS -0.26
- Stochastic Oscillator
- VMEO 30.33
- GHRS 5.15
About VMEO Vimeo Inc.
Vimeo Inc is the all-in-one video software solution, providing the full breadth of video tools through a software-as-a-service model. Its comprehensive and cloud-based tools empower its users to create, collaborate and communicate with video on a single, turnkey platform. The company derives its revenue from SaaS subscription fees paid by customers for subscription plans.
About GHRS GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders. The company is focused on developing novel and proprietary Mebufotenin 5-Methoxy-N, N-Dimethyltryptamine, or 5-MeO-DMT, therapies for the treatment of patients with Treatment-Resistant Depression, or TRD.